WallStreetZenWallStreetZen

NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Ownership - Who owns Lineage Cell Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Lineage Cell Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Brian M. CulleyPresident and CEO2025-02-1112,547$0.65
$8.16kSell
George A. Samuel IiiGeneral Counsel2025-02-112,440$0.65
$1.59kSell
Broadwood Partners LPDirector2025-01-277,894,737$0.76
$6.00MBuy
Jill Ann HoweChief Financial Officer2024-11-2615,000$0.59
$8.85kBuy
George A. Samuel IiiGeneral Counsel2024-11-2615,000$0.60
$9.00kBuy
Michael H. MulroyDirector2024-11-2240,000$0.57
$22.64kBuy
Brian M. CulleyPresident and CEO2024-11-2140,000$0.60
$24.00kBuy
Jill Ann HoweChief Financial Officer2024-08-1610,500$0.89
$9.35kBuy

1 of 1

LCTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LCTX insiders and whales buy or sell their stock.

LCTX Shareholders

What type of owners hold Lineage Cell Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Broadwood Partners LP35.70%81,531,259$74.60MInsider
Broadwood Capital Inc21.70%49,560,992$45.35MInstitution
Neal C. Bradsher20.81%47,515,269$43.48MInsider
Blackrock Inc5.02%11,453,305$10.48MInstitution
Alfred D. Kingsley4.53%10,344,637$9.47MInsider
Vanguard Group Inc3.91%8,919,043$8.16MInstitution
Defender Capital LLC2.76%6,310,873$5.77MInstitution
Raffles Associates LP2.47%5,642,088$5.16MInstitution
George Karfunkel2.18%4,982,217$4.56MInsider
Geode Capital Management LLC1.96%4,485,586$4.10MInstitution

1 of 3

LCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LCTX41.73%58.27%Net Buying
MDWD39.73%0.00%
YMAB62.34%37.66%Net BuyingNet Buying
PRQR38.34%0.00%
GALT11.50%88.50%Net BuyingNet Buying
View Top Biotech Stocks

Lineage Cell Therapeutics Stock Ownership FAQ

Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics (NYSEMKT: LCTX) is owned by 47.89% institutional shareholders, 66.86% Lineage Cell Therapeutics insiders, and 0.00% retail investors. Broadwood Partners LP is the largest individual Lineage Cell Therapeutics shareholder, owning 81.53M shares representing 35.70% of the company. Broadwood Partners LP's Lineage Cell Therapeutics shares are currently valued at $75.01M.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.